Hepatitis Therapeutics Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The Hepatitis Therapeutics by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Hepatitis Therapeutics Market:

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

According to The Business Research Company’s Hepatitis Therapeutics, The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.35 billion in 2023 to $18.89 billion in 2024 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to vaccine development, antiviral medications, public health initiatives, research funding, emerging therapies. .

The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $21.79 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness.. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination..

The rise in hepatitis infection globally is expected to propel the growth of the hepatitis therapeutic market going forward. The rise in hepatitis infection is due to inadequate access to healthcare and vaccinations, an increase in intravenous drug use, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in some parts of the world. For instance, in April 2022, according to World Health Organization (WHO), a US-based united nations public health agency, from 11 nations, at least 169 cases of acute hepatitis of unknown origin have been documented and 350 million individuals worldwide have viral hepatitis B or C, yet for the majority, testing, and treatment are still out of reach. Therefore, the market for hepatitis therapeutics is expanding due to the rise in hepatitis infection.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

The hepatitis therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Drug Class: Oral Antivirals, Immune Modulators

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Product innovations have emerged as the key trend gaining popularity in the hepatitis therapeutics market. Major companies operating in the hepatitis therapeutics market are developing new products to sustain their position in the market. For instance, in November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company received approval from FDA for a medicine called Vemlidy (tenofovir alafenamide) for the treatment of paediatric patients with chronic hepatitis B virus infection. Vemlidy is a targeted prodrug of tenofovir that received FDA approval in 2016 as a once-daily treatment for individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. According to recommendations from the American Liver Foundation, it is a preferred or first-line treatment for persons with chronic HBV and compensated liver disease.

The hepatitis therapeutics market report table of contents includes: